# A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Source: https://onco.cc/trials/nct06597565/  
OnCo record `nct06597565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Prexasertib run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.

## Summary

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC is a phase 2 interventional study registered as NCT06597565 by H. Lee Moffitt Cancer Center and Research Institute, with 43 participants planned, started 2024-09-25. Conditions recorded: Head and Neck Squamous Cell Carcinoma. Interventions recorded: Gemcitabine and ACR-368.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06597565
- Phase: 2
- Setting: A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06597565: https://clinicaltrials.gov/study/NCT06597565

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Prexasertib](https://onco.cc/drugs/prexasertib/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06597565.json